ASH 2020 | Outcomes of TP53-mutant AML with venetoclax and decitabine

Name: Outcomes of TP53-mutant AML with venetoclax and decitabine
Uploaded: 2020-11-30T00:00:00Z
Duration: 2 min 36 s
Description: Marina Konopleva, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, talks on the outcomes of TP53-mutant acute myeloid leukemia patients treated with venetoclax and decitabine. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Marina Konopleva • 30 Nov 2020

ASH 2020

Acute Myeloid Leukemia Leukemia Decitabine Venetoclax

Marina Konopleva, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, talks on the outcomes of TP53-mutant acute myeloid leukemia patients treated with venetoclax and decitabine. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Consultancy (includes expert testimony): AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Amgen, Forty-Seven, Kisoji
Equity ownership: Stocks, Reata Pharmaceuticals
Research funding: AbbVie, Genentech, F. Hoffman La-Roche, Eli Lilly, Cellectis, Calithera, Ablynx, Stemline Therapeutics, Agios, Ascentage, Astra Zeneca
Patents and royalties: Reata Pharmaceuticals